RxDoctor Payments Data

Britni Souther, DO

Hematology & Oncology · Grand Rapids, MINPI 1972996544

Payments from drug & device makers

$7,267in general payments, 2019–2025

Across 368 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$703
  • Novartis$565
  • Gilead$494
  • GSK$459
  • AstraZeneca$455
  • Merck$347
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$7,16799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,267 in reported general payments places this provider in the 60th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$1,531,886
Medicare patients
261
Services billed
56,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide56$830,960
Lenalidomide35$479,567
OjjaaraMomelotinib Dihydrochloride14$361,772
PomalystPomalidomide15$336,229
JakafiRuxolitinib Phosphate17$286,879
VenclextaVenetoclax81$244,213
KisqaliRibociclib Succinate13$190,537
NeulastaPegfilgrastim11$69,625
Imatinib Mesylate21$42,121
EliquisApixaban47$38,486
XareltoRivaroxaban23$27,346
Anastrozole258$11,954
Exemestane18$7,051
Voriconazole18$5,444
Hydroxyurea115$4,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$295$830,96056 claims
GSKOjjaara$459$361,77214 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$36$336,22915 claims
Incyte CorporationJakafi$181$286,87917 claims
AbbVieVenclexta$225$244,21381 claims
NovartisKisqali$565$190,53713 claims
AmgenNeulasta$58$69,62511 claims
PfizerEliquis$155$38,48647 claims
Johnson & JohnsonXarelto$151$27,34623 claims
Lilly USA, LLCOlanzapine$313$10314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →